MedTrace Logo

Karyopharm Expanded Access Program for Selinexor

NCT07215832 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2026-03-02

No results posted yet for this study

Summary

KEAP is an expanded access program designed to provide selinexor to eligible participants outside of a clinical trial before the drug has been given marketing approval by the country's regulatory agency or the drug is commercially available in the country. Patients who do not qualify for an ongoing clinical trial but who might benefit from the investigational medicine may be eligible, provided they have exhausted all other available treatment options. Investigational medicines are provided to patients only through treating physicians who obtain the relevant approval on behalf of their patient from the relevant regulatory agency and follow all applicable safety-reporting regulations of the respective country.

Conditions

Interventions

DRUG

selinexor

KPT-330

Sponsors & Collaborators

  • Caligor Coghlan (CalCog)

    collaborator UNKNOWN

  • Karyopharm Therapeutics Inc

    lead INDUSTRY

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07215832 on ClinicalTrials.gov